Author

Petra Gross-Demel

Institutions: LMU Klinikum, German Center for Infection Research, Institut für Infektions- und Tropenmedizin, Ludwig-Maximilians-Universität München

Observed institutions: LMU Klinikum, German Center for Infection Research, Institut für Infektions- und Tropenmedizin, Ludwig-Maximilians-Universität München

OpenAlex ID: A5093072572

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5

BTZ-043 Shows Good Safety and Strong Bactericidal Activity in a Combined Phase1b/2a Study in Tuberculosis Patients

2023 · Norbert Heinrich, Veronique De Jager, et al. · SSRN Electronic Journal · 5

Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043

2025 · Simon E Koele, Norbert Heinrich, et al. · Journal of Antimicrobial Chemotherapy · 4

Works count: 4

Citation count: 44

H-index: 4

I10-index: 1